5,607 Shares in Baxter International Inc. (NYSE:BAX) Bought by Trust Point Inc.

Trust Point Inc. bought a new position in shares of Baxter International Inc. (NYSE:BAX) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 5,607 shares of the medical instruments supplier’s stock, valued at approximately $213,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. First PREMIER Bank bought a new position in shares of Baxter International during the third quarter worth about $25,000. Innealta Capital LLC acquired a new stake in Baxter International during the 2nd quarter valued at approximately $27,000. LRI Investments LLC bought a new position in Baxter International during the 1st quarter worth approximately $39,000. Versant Capital Management Inc lifted its position in shares of Baxter International by 974.2% in the 2nd quarter. Versant Capital Management Inc now owns 1,332 shares of the medical instruments supplier’s stock worth $45,000 after purchasing an additional 1,208 shares during the period. Finally, Massmutual Trust Co. FSB ADV boosted its stake in shares of Baxter International by 15.1% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 2,069 shares of the medical instruments supplier’s stock valued at $88,000 after purchasing an additional 272 shares during the last quarter. 90.19% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently weighed in on BAX. The Goldman Sachs Group lifted their target price on shares of Baxter International from $36.00 to $40.00 and gave the stock a “neutral” rating in a research note on Thursday, August 8th. JPMorgan Chase & Co. dropped their price objective on Baxter International from $44.00 to $42.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. StockNews.com cut Baxter International from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st. Wells Fargo & Company dropped their price target on Baxter International from $44.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 7th. Finally, Evercore ISI reduced their price objective on shares of Baxter International from $46.00 to $45.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Baxter International presently has a consensus rating of “Hold” and a consensus price target of $42.00.

Baxter International Stock Performance

NYSE BAX opened at $36.86 on Friday. The company has a market cap of $18.78 billion, a P/E ratio of 7.09, a PEG ratio of 1.28 and a beta of 0.59. The company has a fifty day simple moving average of $37.61 and a 200 day simple moving average of $36.63. The company has a current ratio of 1.40, a quick ratio of 0.91 and a debt-to-equity ratio of 1.35. Baxter International Inc. has a 12-month low of $31.70 and a 12-month high of $44.01.

Baxter International (NYSE:BAX) last issued its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. Baxter International had a net margin of 16.51% and a return on equity of 18.06%. The firm had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.75 billion. During the same period last year, the company earned $0.55 earnings per share. The business’s revenue was up 2.8% on a year-over-year basis. Sell-side analysts predict that Baxter International Inc. will post 2.96 earnings per share for the current fiscal year.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.